Clinical Trials Directory

Trials / Sponsors / Janssen Vaccines & Prevention B.V.

Janssen Vaccines & Prevention B.V.

Industry · 49 registered clinical trials.

StatusTrialPhaseStarted
CompletedA Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
Influenza Prevention
Phase 1 / Phase 22023-05-17
TerminatedA Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Ag
Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention
Phase 1 / Phase 22022-04-13
CompletedA Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
COVID-19 Prevention
Phase 32021-11-02
CompletedA Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years
Respiratory Syncytial Virus Prevention
Phase 32021-11-01
CompletedA Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in
Respiratory Syncytial Virus Prevention
Phase 32021-10-08
CompletedA Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadminis
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
Phase 32021-10-04
CompletedA Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Se
Respiratory Syncytial Virus Infection Prevention
Phase 32021-09-29
CompletedA Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive
Coronavirus Disease-2019 (COVID-19) Prevention
Phase 22021-09-27
CompletedA Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
COVID-19 Prevention
Phase 22021-08-27
CompletedA Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vacc
Coronavirus Disease
Phase 22021-08-06
CompletedA Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Resp
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
Phase 32021-07-21
CompletedA Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
COVID-19 Prevention
Phase 32021-06-18
CompletedA Study of Ad26.COV2.S in Healthy Adults (COVID-19)
Healthy
Phase 12021-05-25
CompletedA Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19
Phase 32020-11-12
CompletedA Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women
Healthy
Phase 32020-10-05
CompletedA Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
Phase 32020-09-07
CompletedA Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adol
Healthy
Phase 22020-08-28
CompletedA Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older
Healthy
Phase 22020-07-16
CompletedA Study of Ad26.COV2.S in Adults (COVID-19)
Covid-19 Prevention
Phase 1 / Phase 22020-07-15
CompletedA Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Ebola
Phase 32020-02-18
CompletedA Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mo
Healthy
Phase 32019-10-31
CompletedA Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
Ebola Virus Disease
Phase 22019-08-19
TerminatedA Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Phase 22019-08-01
CompletedA Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory
Respiratory Syncytial Virus
Phase 1 / Phase 22019-01-21
CompletedA Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.pr
Healthy
Phase 12019-01-07
TerminatedSafety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)
Human Papillomavirus Infections
Phase 1 / Phase 22018-09-27
CompletedA Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine
Healthy
Phase 22018-07-31
CompletedA Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Prote
Healthy
Phase 1 / Phase 22018-07-06
CompletedA Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia An
Human Immunodeficiency Virus
Phase 12018-03-05
CompletedA Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26-
Healthy
Phase 22017-12-07
CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (A
Respiratory Syncytial Viruses, Respiratory Tract Infections
Phase 1 / Phase 22017-11-29
CompletedA Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
Healthy
Phase 12017-11-26
TerminatedA Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Pho
HIV-1
Phase 22017-11-03
CompletedAn Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against R
Healthy
Phase 22017-10-16
CompletedA First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent I
Healthy
Phase 12017-10-09
CompletedA Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Fol
Healthy
Phase 1 / Phase 22017-03-31
CompletedA Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year
Healthy
Phase 12016-11-08
CompletedSafety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus
Human Immunodeficiency Virus
Phase 1 / Phase 22016-09-01
CompletedA Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Mu
Healthy
Phase 12016-08-01
CompletedSafety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetra
Healthy
Phase 1 / Phase 22016-07-08
TerminatedLong-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Fi
Hemorrhagic Fever, Ebola
Phase 32016-05-31
CompletedSafety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Gly
Healthy
Phase 12016-03-28
CompletedSafety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MV
Hemorrhagic Fever, Ebola
Phase 22015-12-10
CompletedSafety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-F
Hemorrhagic Fever, Ebola
Phase 22015-11-06
CompletedStaged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN
Ebola Virus Disease
Phase 32015-09-30
CompletedA Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
Healthy
Phase 32015-09-21
CompletedA Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candida
Ebola Viral Disease
Phase 22015-06-15
CompletedA Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy
Healthy
Phase 12015-01-08
CompletedSafety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologo
Healthy
Phase 1 / Phase 22014-12-22